Developing Novel Solutions for the Treatment of Pain
Spinifex Pharmaceuticals is a clinical-stage Australian biotechnology company specialising in the development of products for the treatment of pain.
Spinifex focuses on pain because it is an area of high unmet medical need. Demand for pain drugs continues to increase, fuelling the growth of a market that is expected to be worth US$50 billion annually by 2020. Neuropathic pain, where Spinifex is active, is estimated to affect 1.5 million patients worldwide and is currently poorly treated.
With a range of causes, neuropathic pain can be debilitating and a significant opportunity exists for new candidates that can deliver improved efficacy, side effect profile, time to onset and simplified dosing.
Latest News & Events
23RD DECEMBER 2011 Spinifex set to present at the Biotech Showcase 2012 conference in San Francisco ... More
6TH DECEMBER 2011 Appointment of Spinifex Non-Executive Chairman. ... More
19TH SEPTEMBER 2011 Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia ... More